Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505736 · ClinicalTrials.gov registry record
Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 25
- Enrollment target
NCT03505736 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants.
The verdict
NCT03505736 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatments including chemotherapy and aromatase inhibitors.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Regadenoson
- PROCEDURE Stress Management Therapy
- BIOLOGICAL Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2020-03-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03505736
The ClinicalTrials.gov registry entry for NCT03505736 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03505736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03505736 about?
NCT03505736 is a clinical study titled "Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer". This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatme...
What is the current status of trial NCT03505736?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-06-21. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03505736?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Regadenoson (DRUG), Stress Management Therapy (PROCEDURE), Adenosine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03505736?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.